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Abstract 
PRPF3 is an element of the splicing machinery ubiquitously expressed, yet mutations in this 
gene are associated with a tissue specific phenotype: autosomal dominant retinitis pigmentosa 
(RP). Here we studied the subcellular localization of endogenous and mutant transfected 
PRPF3. We found that: (i) subcellular distribution of the endogenous wild type protein co-
localizes with snRNPs, partially with a nucleolar marker and accumulates in speckles labeled 
by SC35; (ii) in human retinas PRPF3 does not show a distinctive abundance in 
photoreceptors, the cells affected in RP; (iii) RP causing mutant PRPF3, differently from the 
wild type protein, forms abnormally big aggregates in transfected photoreceptor cells. 
Aggregation of T494M mutant PRPF3 inside the nucleus triggers apoptosis only in 
photoreceptor cells. Based on the observation that mutant PRPF3 accumulates in the 
nucleolus and that transcriptional, translational and proteasome inhibition can induce this 
phenomenon in non-photoreceptor cells, we hypothesize that mutation affects splicing factor 
recycling. Noteworthy, accumulation of the mutant protein in big aggregates also affects 
distribution of some other splicing factors. Our data suggest that the mutant protein has a cell 
specific dominant effect in rod photoreceptors while appears not to be harmful to epithelial 
and fibroblast cells. 
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INTRODUCTION 
Retinitis Pigmentosa (RP) is a genetically heterogeneous disease and can be inherited as 
autosomal dominant, autosomal recessive and X-linked trait. Many genes mutated in RP have 
a tissue specific expression in the eye and are either components of the phototransduction 
cascade or of the visual cycle or structural proteins of photoreceptor cells. In contrast, in the 
last years, four pre-mRNA splicing factors have been linked to autosomal dominant RP. 
PRPF31 was found mutated in RP11 patients (1), RP13 is due to mutations in the PRPF8 
gene (2), PAP-1 underlies RP9 (3) and mutations in the PRPF3 gene cause RP18 (4). RP18 
patients show a typical RP phenotype starting at the end of the first decade of life (5). Two 
different missense mutations in English, Danish and Spanish families have been identified in 
the PRPF3 gene and they are localized in two adjacent amino acids of the C-terminal portion 
of the protein, a region well conserved in evolution (4, 6). The link between mutant PRPF3 
and retinal degeneration is completely obscure. It is unclear why mutations in a ubiquitously 
expressed gene cause such a specific phenotype.  
The yeast homologs of PRPF3, PRPF31 and PRPF8 are part of the U4/U6+U5 
spliceosome trimer. Splicing of pre-mRNA is catalyzed in the nucleus by a large 
ribonucleoprotein complex, the spliceosome. The spliceosome consists of the pre-mRNA 
substrate and several small nuclear ribonucleoproteins (snRNPs) together with non-RNP 
splicing factors. Each snRNP particle consists of one (U1, U2 and U5) or two (U4/U6) 
snRNAs associated with many auxiliary proteins. The U6 snRNP is chemically modified by 
snoRNA in the nucleolus before its final assembly into the U6 snRNP. PRPF31 is part of 
U4/U6+U5 trimer (7) while PRPF8 contacts both the 5’ and 3’ splice sites of the intron as 
well as U6 RNA (8). Interaction of PRPF3 protein with PRP4, a key component of the U4/U6 
splicing complex, defined PRPF3 as an snRNP (9). Deletion analysis of the PRPF3 protein 
showed that the central region (amino acids 195-442) binds PRP4 in the U4/U6 complex 
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while the C-terminal part of the protein is involved in binding with snRNAs (9) and with 
PAP-1 (10). Not all splicing factors are always bound to pre-mRNA and assembled into 
active spliceosomes in vivo. Therefore labeling of a splicing factor will detect not only sites 
of splicing but also sites of assembly, transport or storage. snRNPs and non-snRNP splicing 
factors localize in the nucleus in a characteristic speckled pattern. The pattern typically 
contains 20-40 intensely stained speckles against a diffuse nuclear population of splicing 
factors. While PRPF3 is biochemically defined as snRNP, its expression pattern, subnuclear 
localization in mammalian cells and association with different nuclear structures have not 
been characterized in detail yet.  
The aim of our study was to define the molecular mechanism underlying photoreceptor 
cell death caused by PRPF3 mutations. We show that mutations found in RP patients cause 
mislocalization of the PRPF3 protein in a photoreceptor cell line. Aggregation in the 
nucleolus of mutant PRPF3 affects nuclear distribution of other splicing factors. Aberrant 
behavior of mutant PRPF3 is followed by activation of programmed cell death. This 
phenomenon cannot be observed in epithelial or fibroblast cell lines. We otherwise found that 
a similar phenotype can be caused in non-photoreceptor cells when either transcription or 
translation or proteasome are inhibited. Our data provide evidence that disease causing 
mutations are associated with aberrant protein aggregation in photoreceptors and that this 
may be related to defects in recycling of the pre-mRNA splicing factor.  
 
RESULTS 
PRPF3 localization in the retina 
Previous studies based on RT-PCR showed ubiquitous expression of human PRPF3 (4) but 
this analysis did not allow a resolution of transcript distribution at a cellular level. We 
therefore analyzed PRPF3 protein localization in sections of adult human retina. PRPF3 
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protein was localized to the nuclei of photoreceptor cells, interneurons and ganglion cells. 
Relatively higher levels were detected in ganglion and inner nuclear layers and lower levels 
in the outer nuclear layer where photoreceptors are localized (Figure 1A). Similarly, murine 
Prpf3 mRNA showed an uneven distribution in the adult where a prevalent expression was 
detected in ganglion cells and in the inner nuclear layer (Supplementary figure 1B). Higher 
levels of expression were detected 8 days after birth (P8) in the outer nuclear layer of a not 
fully developed retina when rods have not completed their differentiation yet (Supplementary 
figure 1A).  
 
Subcellular distribution of wild type and mutant PRPF3 
In order to characterize subcellular distribution of endogenous PRPF3 we compared PRPF3 
protein localization with known proteins labeling different nuclear compartments in HeLa 
cells. PRPF3 co-localized with snRNPs inside the nuclei (Figure 1B-D) and also partially 
overlapped with splicing nuclear speckles detected with an antibody to the SC35 protein, a 
non-snRNP splicing factor of the SR family of proteins (Figure 1E-G). Low amount of 
PRPF3 was observed inside the nucleolus, as shown by co-localization with the nucleolar 
marker fibrillarin (Figure 1 H-J, arrow). PRPF3 staining inside the nucleolus varied from cell 
to cell when compared to fibrillarin suggesting that PRPF3, as other snRNPs, transiently 
enter the nucleolus. Conversely, we detected no co-localization of PRPF3 with coilin, that 
labels Cajal bodies (Figure 1K-M).  
In order to define whether mutations found in RP patients affected localization of PRPF3, 
we cloned human PRPF3 in frame with EGFP at the N-terminus. The use of tagged wild 
type, P493S mutant and T494M mutant PRPF3 was motivated by the requirement to 
distinguish transfected proteins from the endogenous protein. Transfected wild type PRPF3 
localized to the nucleus of HeLa cells with a dot-like pattern, and more abundantly in the 
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nucleolus when compared to endogenous PRPF3 (Figure 1N, arrow). Similarly to the wild 
type protein, both mutations found in patients were observed inside the nucleus of transfected 
cells, in dot-like structures and in the nucleolus (Figure 1O and P). To rule out the possibility 
that subcellular localization of the transfected proteins was affected by the EGFP tag, we 
cloned wild type and mutant PRPF3 in frame with a His tag at the C-terminus and obtained 
identical results (data not shown). Therefore transfected protein localized in speckles (as seen 
by co-localization with SC35, figure 5) however over-expression causes storage of extra 
protein in the nucleolus. 
 
Aberrant and detrimental behavior of mutant PRPF3 in a photoreceptor cell line 
Wild type and mutant PRPF3 showed a similar subcellular localization in epithelial cells in 
culture. However, mutations in patients cause a specific phenotype in rod photoreceptors. We 
therefore tested subcellular distribution in in vitro cultured photoreceptor cells. 661W cells 
are a good model for in vitro studies of photoreceptors because they are an immortalized 
mouse cell line derived from transgenic mice expressing the SV40 T antigen under the 
control of the photoreceptor specific IRBP promoter (11). These cells, under regular culture 
conditions, do not show a very specific morphological and molecular photoreceptor 
phenotype (Supplementary figure 1C). Treatment of 661W cells with sodium butyrate, as 
previously reported for Y79 human photoreceptor tumor cells (12), induced differentiation as 
shown by elongated shape, upregulation of rhodopsin and phosphodiesterase 6β 
(Supplementary figure 1D) and reduction of progenitor marker nestin (Supplementary figure 
1G-H). Differently from Y79, treatment of 661W with sodium butyrate did not activate 
apoptosis (Figure 4B and D). We also observed that sodium butyrate reduced expression of 
endogenous Prpf3 (Supplementary figure 1E-F). This result was in line with the observation 
that in vivo expression in photoreceptors decreased upon differentiation (Supplementary 
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figure 1A-B). These findings, together with the previous characterization of this cell line (11), 
confirmed that 661W in the presence of sodium butyrate can be a valuable system for 
functional studies in photoreceptor cells. Hence, we transfected wild type and mutant EGFP 
tagged PRPF3 in 661W cells and we allowed in vitro differentiation by treatment with 
sodium butyrate. Wild type PRPF3 localized to the nucleus of photoreceptors with a dot-like 
pattern in addition to a diffuse staining (Figure 2A-B). On the contrary, T494M mutant 
PRPF3 accumulated in a big aggregate inside the nucleus (Figure 2D, arrow). Formation of 
big aggregates was subsequent to treatment with sodium butyrate of 661W cells (Figure 2C-
D). By introducing a negatively charged residue (aspartate, T494D), that may mimic the 
effect of putative phosphorylation at the threonine residue (13), we generated a different 
mutation in amino acid 494 of PRPF3 protein. Interestingly, T494D mutant behaves like the 
wild type protein (Figure 2E). Similar results were obtained with P493S mutant protein and 
with differently tagged constructs (Supplementary Figure 2). 
In order to define whether mutant PRPF3 behaved abnormally also in photoreceptors in 
vivo, we electroporated neonatal murine eyes with the EGFP tagged constructs and analyzed 
protein distribution 13 days later, when photoreceptor cells differentiated. While wild type 
PRPF3 localized with a dot-like pattern inside the nuclei of electroporated photoreceptors 
(Figure 3A), T494M mutant PRPF3 formed, similarly to 661W cells in vitro, a big aggregate 
detectable inside photoreceptor nuclei (Figure 3B). 
We speculated that aggregation of a pre-mRNA splicing factor could affect distribution of 
other components of the splicing machinery and found SC35 in the aggregate together with 
the mutant PRPF3 (Figure 2F-K). Differently, no major change of other snRNPs was induced 
by expression of mutant PRPF3 (Figure 2L-Q).  
Finally, we assessed whether aggregation of mutant PRPF3 is detrimental to 
photoreceptors in vitro. No TUNEL positive cells were detected after transfection of the wild 
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type protein with or without sodium butyrate (Figure 4A-D and I), on the contrary expression 
of T494M mutant PRPF3 in the presence of sodium butyrate strictly correlated with 
chromatin fragmentation and apoptosis (Figure 4E-H). A time course experiment showed that 
12 hours after transfection aggregation of T494M mutant PRPF3 could be observed in 25% 
of transfected cells however no apoptosis could be detected by TUNEL staining yet. Six 
hours later the number of T494M PRPF3 expressing cells decreased compared to wild type 
transfected cells suggesting that cell demise occurred. Consistently, most of the transfected 
cells showed amassed nuclear T494M PRPF3 and chromatin fragmentation and 36 hours 
after transfection no cell that expressed mutant PRPF3 could be found (Figure 4I). Similar 
experiments were performed in HeLa and NIH3T3 cells (Supplementary figure 3G-L and 
data not shown) and, unlike as presented with 661W cell line, no indication of apoptosis was 
observed. 
 
Nuclear distribution of mutant PRPF3 is affected by transcription, translation and 
proteasome inhibition  
Aggregation of mutant PRPF3 appears to be cell type specific and this may be correlated 
to specific physiological conditions of differentiated photoreceptors. Previous studies showed 
that treatment of cells with transcriptional inhibitors reduces splicing activity and foci 
associated with RNA processing undergo dynamic changes, in particular, speckles labeled 
with SC35 become fewer, increase in size and round up (14).  To determine whether 
localizations of wild type and mutant PRPF3 could be affected by the transcriptional activity 
of the cell, transfected HeLa cells were treated with actinomycin D, inhibitor of nucleolar 
RNA and mRNA synthesis, or α-amanitin, inhibitor of transcription mediated by RNA 
polymerase II. Similar results were observed with both drugs, but a stronger phenotype was 
observed when both mRNA and nucleolar RNA syntheses were inhibited. Inhibition of 
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transcription caused wild type PRPF3 to diffuse inside the nucleus and to lose the dot-like 
pattern (Figure 5A), on the contrary T494M mutant PRPF3 accumulated in a single big mass 
(Figure 5D). We also observed that the abnormal behavior of mutant PRPF3 caused changes 
in the distribution of SC35 (Figure 5E-F), preventing it to form typical big speckles (Figure 
5B). Similarly, inhibition of either protein synthesis or proteasome caused abnormal behavior 
of T494M mutant PRPF3 that formed big masses aggregating with SC35 (Figure 5G-R). 
When we analyzed localization of other snRNPs we found that after treatment with 
proteasome inhibitor, Y12 completely co-localized with wild type PRPF3 and only partially 
co-localized with mutant PRPF3 in the big aggregate (Figure 5S and T). 
Formation of aggregates inside the nucleus was specific for these treatments. In fact, 
treatment with sodium butyrate, a histone deacetylase inhibitor, or thapsigargin, that inhibits 
ER-associated Ca2+-ATPase and disrupts Ca2+ homeostasis, did not cause changes in 
subcellular distribution of mutant PRPF3 that behaved like the wild type protein 
(Supplementary figure 3). 
We finally wanted to characterize in which nuclear compartment T494M mutant PRPF3 
aggregated. We performed double labeling of transfected cells with other markers of different 
nuclear compartments. Mutant PRPF3 formed a single big aggregate co-localizing with 
nucleolar marker fibrillarin (Figure 5U).  
 
DISCUSSION 
In the recent years four genes encoding pre-mRNA splicing factors have been associated to 
autosomal dominant RP. They are all component of the U4/U6.U5 tri-snRNP complex, and 
this suggests that mutations in these genes may activate a common detrimental pathway in 
photoreceptor cells. The mechanism by which mutations in pre-mRNA splicing factor 
proteins cause the selective demise of photoreceptors is currently unknown. In fact, a direct 
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link between the function of U4/U6.U5 tri-snRNP complex and photoreceptor cells has not 
been discovered and expression analyses of these genes did not support a cell specific 
function (2-4, 15).  
In this study we report tissue and subcellular distribution of endogenous PRPF3. Protein 
localization experiments did not show prevalent PRPF3 expression in photoreceptors, the 
cells that undergo degeneration in RP patients. Subcellular distribution is consistent with 
previous studies characterizing PRPF3 as a pre-mRNA splicing factor (16, 17). Nuclear 
localization was similar to other snRNPs, and also partially concentrated in speckles as 
shown by co-localization with the SR protein SC35. Interestingly, we observed low amounts 
of the protein inside the nucleolus. Some of the U4/U6.U5 tri-snRNP complex components, 
like U6 snRNP, are modified in the nucleolus before final assembly. Similarly, PRPF3 may 
require chemical modifications in the nucleolus to become active.  
Our analysis of wild type versus mutant PRPF3 brought to light an abnormal behavior of 
the protein subsequent to mutations found in RP patients. Interestingly, this phenotype 
manifested only upon differentiation to photoreceptors. This indicates that the abnormal 
behavior requires either a cell specific factor expressed in differentiated rods or a metabolic 
change consequent to differentiation. This last hypothesis is supported by previous reports 
describing reorganization of subnuclear structures during neuronal differentiation (18). Of 
note is the observation that aggregation of mutant PRPF3 can also be caused by changes in 
transcriptional activities or protein translation and degradation. As spliceosome assembly is a 
dynamic and reversible process, it is possible that mutant PRPF3 is sensitive to the turnover 
determined by proteasome-mediated degradation. In fact proteasome inhibition may stabilize 
the dynamic interaction of mutant PRPF3 with other splicing factors in the nucleolar region. 
A similar effect was previously reported on interaction of Myc and PML in the nucleolus 
(19). Our data indicate a defect in recycling of mutant PRPF3 in these stressful conditions. It 
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is known that in the absence of nascent RNAs, as in conditions of transcriptional inhibition, 
splicing factors cannot find a target and therefore they return to their storage or assembly 
sites (14, 20). This can be visualized by rounding up of speckles containing SC35 in response 
to transcription inhibitors and diffuse staining of snRNP proteins. On the contrary, mutant 
PRPF3 amassed in big aggregates in the nucleolus and this affects also localization of SC35. 
Other snRNPs (sm proteins) are otherwise only marginally affected by mutant PRPF3. This 
can be due to specific properties of distinct splicing factors that can reside in different nuclear 
compartments for shorter or longer time and specifically in the nucleolus. We also observed 
that mutant PRPF3, from a condition similar to the wild type protein, slowly accumulated in a 
big protein mass close to the nucleolar region. Interestingly, this behavior is similar to the 
Smn protein, mutated in spinal muscular atrophy, that was shown to co-localize with 
fibrillarin in the nucleolus of neurons, and this raised the hypothesis of a neuronal specific 
function of this protein (21). The formation of aggregates appears to be specific to the 
mutation Threonine 494 to Methionine, because mutation of the threonine to an acidic amino 
acid behaves like the wild type protein. Noteworthy, the specific mutation T494M has been 
found several times in RP18 patients and no founder effect was demonstrated (4, 6).  
In conclusion, our data suggest that mutant PRPF3 causes mislocalization of splicing factors 
and forms aggregates that can be detrimental to the photoreceptor cell. We can envision the 
possibility that the pathogenetic mechanism is similar also for mutations in other pre-mRNA 
splicing factors. In fact, downregulation of PRPF31 inhibits formation of U4/U6.U5 tri-
snRNP causing accumulation of snRNPs in bigger nuclear speckles (22). Further studies are 
needed to define whether aggregates found with mutant PRPF3 and those caused by 
haploinsufficiency of PRPF31 have similar effects on other splicing factors in the nucleus 
and whether they impair splicing of rod specific genes. Two possible outcomes can develop 
from PRPF3 mutation: the mutation leads to haploinsufficiency or the mutant protein has a 
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cell specific dominant negative effect in photoreceptor cells only. With all the above evidence 
shown in this paper we favor the second hypothesis. In fact we demonstrated a detrimental 
behavior of mutant PRPF3 only upon differentiation of rod photoreceptor cells. Future 
studies will address biochemical changes underlying the formation of nuclear aggregates by 
mutant PRPF3. 
 
MATERIALS AND METHODS 
PRPF3 constructs 
Human wild type and mutant (P493S and T494M) PRPF3 were cloned in the pTriEx-1 
expression vector (Novagen, La Jolla, CA, USA) using EcoRV and XhoI restriction sites.  
EGFP-PRPF3- pTriEx-1, wild type and T494M mutant, were generated by amplification 
with Pfu DNA polymerase (Promega, Milan, Italy) starting from PRPF3 in pTriEx-1 (wild 
type and T494M) using as primers: 5’HPRPF3: 
CGGAATTCGCACTGTCAAAGAGGGAGCTG and 3’HPRP3: 
CGGGATCCAATCACTTAGTGATGGTGATG. The PCR products were cloned in the 
pTriEx-1 expression vector in which EGFP was cloned at the XbaI-XhoI sites to obtain a 
PRPF3 tagged at the N-terminal (Novagen. La Jolla, CA, USA).  
T494D mutant PRPF3 was generated by DNA amplification using QuikChangeXL site-
directed mutagenesis kit (Stratagene) and the mutagenized primer 
(5’GTTCAAGACCCCGACAAGGTAGAAGCC). Underlined characters indicate base 
substitutions. 
 
Cell transfection and immunohistochemistry 
HeLa cells and 661W cells (11) were grown at 37°C and 5% CO2 in DMEM supplemented 
with 10% FBS, penicillin (100U/ml) and streptomycin (50μg/ml).  
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HeLa cells were seeded on covereslips while 661W cells were seeded on ECM substrate 
(Sigma, Milan, Italy) at the concentration of 104 per cm2. Cells were cultured overnight and 
transfected with 0.4μg of DNA using PolyFect transfection reagent (Qiagen, Milan, Italy) 
according to the manufacturer’s instructions. 661W cells were cultured for one day after 
transfection and then treated with 4mM Na Butyrate, 50μM taurine and 50ng/ml EGF.  
For either transcription or translation or proteasome inhibition 24 hours after transfection 
HeLa cells were treated for 6 hours with either actinomycin D (5μg/ml, SIGMA, Milan, Italy) 
or α-amanitin (50μg/ml, SIGMA, Milan, Italy) or the proteasome inhibitor carbobenzoxy-L-
leucyl-L-leucyl-L-leucinal (MG132, 50μM in DMSO, Calbiochem, Darmstadt, Germany) or 
cycloheximide (0.1μg/μl, SIGMA, Milan, Italy).  
As primary antibodies we used: anti-human PRPF3 (clone 4E3, MBL, Japan) 1:200, anti-
His tag (Qiagen, Milan, Italy) 1:50, anti-SC35 (SIGMA, Milan, Italy) 1:200, anti-Sm proteins 
(clone Y12, Lab Vision Corporation, Milan, Italy) 1:100, anti- Fibrillarin (72B9) 1:10 (23), 
anti-coilin (clone pd, SIGMA, Milan, Italy) 1:100, anti-Rhodopsin (RET-P1, SIGMA, Milan, 
Italy) 1:10000. Slides were photographed using a Zeiss Axioplan microscope.  
Immunohistochemistry was performed on cryosections of human retinas (a donation of 
the Italian Eye Bank, “Fondazione Banca degli Occhi del Veneto” Venice; two different 
individuals were analyzed). Retinas were incubated with anti-human PRPF3 and stained 
using Vectastain ABC kit (Vector laboratories, Burlingame, CA, USA) following 
manufacturer’s instructions. Images were acquired by the AxioCam MRc camera (Carl 
Zeiss), using the Axiovision 3.0 software (Carl Zeiss), with a format of 1030 x 1300 pixel. 
 
In situ hybridization 
The Prpf3 antisense probe was obtained by linearization of the EST clone 5344086 (IMAGE) 
with EcoRI and transcription with T7 RNA polymerase. Digestion of the same plasmid with 
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XhoI and transcription with SP6 RNA polymerase generated the sense control probe. Eyes at 
postnatal day 8 (P8) and 2 month (Adult) old C57BL6 mice were analyzed by in situ 
hybridization on sectioned tissue as previously described (24). 
 
Retina electroporation 
All procedures on mice were performed in accordance with institutional guidelines for animal 
research. Wild type and T494M PRPF3-EGFP (PRP3-EGFP-pTriEx-1) were electroporated 
in neonatal CD1 mice. Newborn mouse pups were anesthetized by chilling on ice and eyelids 
were opened using a scalpel. After piercing the sclera with a 30-gauge needle, the DNA 
solution (6μg/μl) was delivered subretinally by using a Hamilton syringe as described (25). 
After DNA injection five 100V square pulses of 50ms duration were applied with a T820 
electroporation system (BTX, San Diego, USA). Electroporated retinas were harvested 13 
days after electroporation, fixed with 4% paraformaldehyde in PBS over night at 4°C. After 
cryoprotection with 30% sucrose in PBS and embedding in gelatin, cryosections (12μm) were 
cut on a cryostat. Retina sections were analyzed with Zeiss Axioplan microscope. 
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LEGENDS TO FIGURES 
Figure 1. Expression and subcellular localization PRPF3.  
A: immunolocalization of the PRPF3 protein in adult human retina. onl: outer nuclear layer; 
inl: inner nuclear layer; gc: ganglion cell layer. Scale bar 100μm. 
B, E, H and K: immunolocalization of PRPF3 in HeLa cells. C: immunolocalization of 
snRNPs with Y12 antibody. F: immunolocalization of SC35. I: immunolocalization of 
fibrillarin. L: immunolocalization of coilin. D, G, J and M show merged images and DAPI 
staining (blue) of nuclei.  
HeLa cells were transfected with EGFP-tagged wild type (N), P493S mutant (O) and T494M 
mutant (P) PRPF3. Arrows indicate nucleolar localization of transfected PRPF3 protein. 
Scale bar in B - P: 10μm. 
 
Figure 2. Expression of transfected wild type and mutant PRPF3 in a photoreceptor cell 
line. 
Wild type and T494M mutant EGFP-PRPF3 were transfected in 661W cells and expression 
was analyzed with (B, D and E-Q) or without (A and C) treatment with sodium butyrate. 
Wild type PRPF3 localizes into the nucleus with a spotty patter (in green in panels A and B). 
T494M mutant PRPF3 aggregates inside the nucleus of 661W cells treated with sodium 
butyrate (green in panel D, arrow). T494D mutant PRPF3 maintains a spotty pattern inside 
the nucleus of 661W cells treated with sodium butyrate (green in panel E). Cells were also 
stained with an anti-rhodopsin antibody (red in A-E).  
F-K: co-localization of EGFP-PRPF3 (green) and SC35 (red). Blue in merged images (H and 
K) is DAPI staining of nuclei. 
L-Q: co-localization of EGFP-PRPF3 (green) and snRNPs (red). Blue in merged images (N 
and Q) is DAPI staining of nuclei. 
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Figure 3. Expression of wild type and mutant PRPF3 in electroporated retina. 
Wild type and T494M mutant PRPF3 were in vivo electroporated in murine retinas. While 
wild type PRPF3 localizes inside the nuclei with a spotty pattern (blow-up in A), T494M 
mutant PRPF3 forms aggregates in photoreceptor nuclei (blow-up in B). Photoreceptors are 
defined based on histologial localization of nuclei in the retina section. Blue is DAPI staining 
of nuclei. Scale bar: 100μm. 
 
Figure 4. Expression of T494M mutant PRPF3 causes cell death in 661W photoreceptor 
cells 
A-H: 661W cells were transfected with either wild type (A-D) or T494M mutant EGFP-
PRPF3 (E-H). After transfection cells were either treated (C-D and G-H) or not treated (A-B 
and E-F) with sodium butyrate. Nuclear localization of transfected proteins is shown in A, C, 
E, G. TUNEL staining is shown in B, D, F, H.  
I: Time course of transfection experiments. Histogram reports percentage of transfected cells 
with either wild type PRPF3 (striped bars) or T494M mutant PRPF3 (black bars), percentage 
of trasfected cells presenting aggregate formation (gray bar) and undergoing apoptosis (white 
bar) after transfection with T494M mutant PRPF3. 
 
Figure 5. Effects of transcription, translation and proteasome inhibitors on wild type 
and mutant PRPF3 subcellular localization. 
HeLa cells were transfected with either wild type (A-C, G-I, M-O and S) or T494M (D-F, J-
L, P-R and T-U) EGFP-PRPF3 (green) and immunolabelled with either anti-SC35 antibody 
(red in B, C, E, F, H, I, K, L, N, O, Q, R), or anti-snRNP antibody Y12 (red in S and T) or 
anti-fibrillarin (red in U). Cells were treated for 12 hours with either actinomycine D to block 
21 
transcription (A-F) or cycloheximide to block translation (G-L) or proteasome inhibitor (M-
U). Merged images are shown in C, F, I, L, O, R-U where blue is DAPI staining of nuclei. 
T494M mutant PRPF3 aggregates inside the nucleolus (U). Scale bar: 10μm. 
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